Navigation Links
Study finds Viagra increases release of key reproductive hormone
Date:8/23/2007

Researchers at the University of Wisconsin-Madison report this month that sildenafil increases the amount of oxytocin released by stimulation of the posterior pituitary gland, a small structure directly underneath the brain that regulates hormone levels in response to neural signals.

The finding is the first indication of a chemical mechanism through which erectile dysfunction drugs like Viagra may have physical effects besides increasing blood flow to sexual organs, says study author Meyer Jackson, a physiology professor at the UW-Madison School of Medicine and Public Health.

Sometimes called the "love hormone" or "cuddle chemical," oxytocin plays several important roles in social interactions and reproduction, including triggering uterine contractions and lactation. It is also released during orgasm and has been linked to sexual arousal.

Oxytocin release is regulated by an enzyme that acts like a braking system, limiting hormone release by dampening neural excitation of the cells. This same enzyme, phosphodiesterase type 5, also limits blood flow by contracting the muscles around blood vessels.

In both places, sildenafil works by blocking this enzyme, essentially releasing the brakes, explains Jackson. In blood vessels, relaxing smooth muscle increases blood flow, which corrects erectile dysfunction, and in the posterior pituitary, the cells become more responsive. "The same stimulation will produce more [oxytocin] release." He says, "I think this is a missing link in terms of trying to sort out the issues around whether there are additional effects of phosphodiesterase type 5 inhibitors," which include Viagra, Levitra and Cialis.

The new report was published online Aug. 9 and appears in an upcoming issue of the Journal of Physiology. In the study, the scientists measured oxytocin released from rat pituitaries in response to neural stimulation. When the pituitaries were treated with sildenafil, they responded to the stimulation by releasing three times as much oxytocin as they did without the drug. Importantly, the drug had little if any effect on hormone release in the absence of stimulation, Jackson says. "Erectile dysfunction drugs do not induce erections spontaneously, they enhance the response to sexual stimulation," he says. "The same thing is happening in the posterior pituitary - Viagra will not induce the release of oxytocin on its own, but it will enhance the amount of release you get in response to electrical stimulation."

Though he doesn't think his findings raise any significant safety issues related to Viagra use, he does think it provides strong rationale for studies of additional effects and new potential uses. "A big question raised by our study is, will sildenafil do the same thing to the nerve terminals that release oxytocin [in the brain]"" he says. The cells that supply oxytocin to the pituitary come from a brain structure called the hypothalamus, which also sends hormones throughout the brain.

Though sildenafil's effects on these pathways are still unknown, work by other researchers has shown that oxytocin-sensitive cells in the brain play a role in the neural control of erectile responses, suggesting that Viagra and its kin may work through multiple channels.

The famous blue pills could have other uses as well. Oxytocin has been linked to the ability to make strong social bonds, while sildenafil was recently shown to improve hamsters' abilities to adjust the timing of their internal clocks to overcome simulated jet lag. "This is one piece in a puzzle in which many pieces are still not available," Jackson says. "But it raises the possibility that erectile dysfunction drugs could be doing more than just affecting erectile dysfunction."


'/>"/>
Contact: Meyer Jackson
mjackson@physiology.wisc.edu
608-262-9111
University of Wisconsin-Madison
Source:Eurekalert

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... -- Cousins Properties (NYSE: CUZ ) announced today ... signed a 10-year, approximately 125,000 square-foot lease at Corporate Center, ... the Westshore submarket of Tampa, FL. ... Corporate Center for their new location in Tampa ... executive officer of Cousins Properties. "Amgen is a cutting-edge global ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), ... the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is ... ) and the US National Institutes of Health. ... ... ...
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics Officer ... Subha Madhavan , Ph.D., will be speaking at ... Panels. On Monday, March 27, 2017, she will be ... More Usable for Research and Care" (from 10:30 a.m. ... 2017, she will be a participant in the "Making ...
(Date:3/27/2017)... ... ... PMG Research is pleased to announce its participation in the 2nd ... Boston on April 3-4, 2017. The CTC conference focuses on how the industry is ... closer to the patient. Clinical Trial Collaborations also will present an inaugural conference on ...
Breaking Biology Technology: